SCHEMBL969727

SCHEMBL969727

CCn1ccc(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.46
PLA2G4A P47712 1/20 0.44
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.40
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HCAR3 P49019 1/20 0.37
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CNR1 P21554 1/20 0.36
DAO P14920 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7755595 0.84 KDM5A (0.48) AKR1B1PLA2G4AALDH1A1POLBTSHR
SCHEMBL4553409 0.82 AKR1B1 (0.41) AKR1B1POLBTSHRL3MBTL1CNR1
SCHEMBL22572028 0.82 MAPT (0.41) AKR1B1ALDH1A1TSHRL3MBTL1SMN1; SMN2
SCHEMBL25352235 0.79 TSHR (0.44) TSHRKDM4EMEN1MAPTKMT2A
SCHEMBL15498815 0.79 AOC2 (0.43) AKR1B1ALDH1A1POLBL3MBTL1KDM5A
SCHEMBL25691915 0.79 AKR1B1 (0.42) AKR1B1PLA2G4AHCAR3KDM4EKMT2A
SCHEMBL21413172 0.78 CNR1 (0.56) PLA2G4AALDH1A1POLBTSHRTP53
SCHEMBL22291138 0.78 CNR1 (0.56) PLA2G4AALDH1A1POLBTSHRTP53
SCHEMBL9150323 0.78 CNR1 (0.56) PLA2G4AALDH1A1POLBTSHRTP53
SCHEMBL6773677 0.77 CA12 (0.50) ALDH1A1TSHRMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 EP disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
WO-2025038462-A2 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2025-02-20 WO disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 WO disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 CN disclosed
WO-2023233864-A1 OPTICAL FILM, COMPOSITION FOR COLORED LAYER FORMATION, DIPYRROMETHENE COBALT COMPLEX, AND DISPLAY DEVICE 凸版印刷株式会社 2023-12-07 WO disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
EP-1466902-A1 ANDROGEN RECEPTOR ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed
US-6713634-B2 SEROTONIN RECEPTOR ANTAGONIST DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-03-30 US disclosed
US-20030166926-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2003-09-04 US disclosed
US-6489473-B2 FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION SUNTORY LIMITED (JP) 2002-12-03 US disclosed
US-20020072515-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2002-06-13 US disclosed
EP-0807632-B1 PYRROLOAZEPINE DERIVATIVES SUNTORY LTD (JP) 2002-04-17 EP disclosed
US-6258805-B1 TREATMENT OF BRAIN DISORDERS AND HYPERTENSION SUNTORY LIMITED (JP) 2001-07-10 US disclosed
US-5962448-A Pyrroloazepine derivatives SUNTORY LIMITED (JP) 1999-10-05 US disclosed
EP-0807632-A1 PYRROLOAZEPINE DERIVATIVES SUNTORY LIMITED (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 AKR1B1 3557/4885PLA2G4A 1995/4885ALDH1A1 1991/4885
US-20020072515-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C AKR1B1 2474/4885PLA2G4A 1471/4885ALDH1A1 2580/4885
US-20030166926-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C AKR1B1 2221/4885PLA2G4A 1494/4885ALDH1A1 2451/4885
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof LPAR2, LPAR1, LPAR5 AKR1B1 789/4885PLA2G4A 15/4885ALDH1A1 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.